Table 1.
Baseline characteristics of the study population
| Total | Calverley | CCLS | ECLIPSE | EUROSCOPE | ISOLDE | LHS | Szafranski | |
|---|---|---|---|---|---|---|---|---|
| Patient, N (%) | 8686 (100) | 90 (1.0) | 231 (2.7) | 1500 (17.3) | 982 (11.3) | 260 (3.0) | 5591 (64.4) | 32 (0.4) |
| Age, y (SD) | 51.9 (9.1) | 62.4 (9.4) | 58.9 (9.1) | 60.2 (9.0) | 52.5 (7.6) | 63.9 (8.0) | 48.4 (6.8) | 66.3 (8.5) |
| Women, N (%) | 3229 (37.2) | 25 (27.8) | 94 (40.7) | 665 (44.3) | 276 (28.1) | 81 (31.2) | 2085 (37.3) | 3 (9) |
| Current smoker, N (%) | 4849 (55.9) | 29 (32.2) | 175 (75.8) | 426 (28.7) | 982 (100) | 126 (48.5) | 3096 (55.4) | 15 (46.9) |
| GOLD grade, N (%) | ||||||||
| 1 | 3674 (42.3) | 12 (13.3) | 105 (45.5) | 575 (38.3) | 354 (36.0) | 9 (3.5) | 2619 (46.8) | 0 (0) |
| 2 | 5012 (57.7) | 78 (86.7) | 126 (54.5) | 925 (61.7) | 628 (64.0) | 251 (96.5) | 2972 (53.2) | 32 (100) |
| FEV1 | ||||||||
| Absolute, Litre | 2.62 (0.73) | 1.84 (0.48) | 2.54 (0.80) | 2.35 (0.96) | 2.60 (0.62) | 1.83 (0.44) | 2.75 (0.63) | 1.62 (0.29) |
| % predicted | 77.8 (14.4) | 63.7 (13.5) | 79.6 (15.6) | 81.6 (25.6) | 74.6 (11.6) | 61.9 (8.6) | 78.4 (9.1) | 56.0 (6.0) |
| BMI, kg/m2 | 25.7 (4.3) | 25.9 (5.3) | 25.5 (4.2) | 27.3 (5.4) | 24.5 (3.3) | 25.2 (4.3) | 25.5 (3.9) | 26.0 (5.3) |
| BMI category, N (%) | ||||||||
| Underweight (BMI < 18.5) | 163 (1.9) | 5 (5.6) | 3 (1.3) | 30 (2.0) | 21 (2.1) | 13 (5.0) | 90 (1.6) | 1 (3.1) |
| Normal (BMI 18.5–25.0) | 3945 (45.4) | 41 (45.6) | 118 (50.1) | 510 (34.0) | 555 (56.5) | 118 (45.4) | 2589 (46.3) | 14 (43.8) |
| Overweight (BMI 25.1–30.0) | 3340 (38.5) | 27 (30.0) | 71 (30.7) | 589 (39.3) | 354 (30.0) | 93 (35.8) | 2194 (39.2) | 12 (37.5) |
| Obese (BMI > 30.1) | 1238 (14.3) | 17 (18.9) | 39 (16.9) | 371 (24.7) | 52 (5.3) | 36 (13.8) | 718 (12.8) | 5 (15.6) |
| Follow-up, mo | 36 (median) | |||||||
BMI body mass index, CCLS City Lung Study, ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study, EUROSCOPE European Respiratory Society study on COPD, GOLD Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grades, ISOLDE Inhaled Steroids in Obstructive Lung Disease in Europe, LHS lung health study, mo moth, N number, SD standard deviation, y, year